Novolog Pharm (Israel) Today
| NVLG Stock | 161.20 12.70 8.55% |
PerformanceVery Weak
| Odds Of DistressLow
|
Novolog Pharm is trading at 161.20 as of the 23rd of March 2025, a 8.55 percent increase since the beginning of the trading day. The stock's open price was 148.5. Novolog Pharm has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 21st of February 2025 and ending today, the 23rd of March 2025. Click here to learn more.
Novolog Ltd operates as a health logistics company in Israel. Novolog Ltd operates as a subsidiary of Pharm-Up Ltd. Novolog Ltd operates under Medical Care classification in Israel and is traded on Tel Aviv Stock Exchange. The company has 508.7 M outstanding shares. More on Novolog Pharm Up 1966
Moving together with Novolog Stock
Moving against Novolog Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Novolog Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Novolog Pharm's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Novolog Pharm or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO of a Subsidiary | Rafi Friedman |
| Business Concentration | Health Care, Health Care Providers & Services, Medical Care, Healthcare (View all Sectors) |
Novolog Pharm Up 1966 (NVLG) is traded on Tel Aviv Stock Exchange in Israel and employs 900 people. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.09 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Novolog Pharm's market, we take the total number of its shares issued and multiply it by Novolog Pharm's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Novolog Pharm Up operates under Health Care Providers & Services sector and is part of Health Care industry. The entity has 508.7 M outstanding shares.
Novolog Pharm Up 1966 has accumulated about 107.97 M in cash with 83.39 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.31.
Check Novolog Pharm Probability Of Bankruptcy
Ownership AllocationNovolog Pharm Up maintains a total of 508.7 Million outstanding shares. Novolog Pharm Up 1966 holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Novolog Ownership Details
Novolog Pharm Up Risk Profiles
Although Novolog Pharm's alpha and beta are two of the key measurements used to evaluate Novolog Pharm's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.61 | |||
| Standard Deviation | 2.37 | |||
| Variance | 5.6 | |||
| Risk Adjusted Performance | (0.06) |
Novolog Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Novolog Pharm without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Headlines Timeline Now
Headlines TimelineStay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |
| All Next | Launch Module |
Novolog Pharm Corporate Management
Elected by the shareholders, the Novolog Pharm's board of directors comprises two types of representatives: Novolog Pharm inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novolog. The board's role is to monitor Novolog Pharm's management team and ensure that shareholders' interests are well served. Novolog Pharm's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novolog Pharm's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Maoz Ramon | Chief Ltd | Profile | |
| David Shmuelov | Chief Company | Profile | |
| Eran Taus | Chief Officer | Profile | |
| Armin Shaun | Chief Ltd | Profile | |
| Amir Shachar | Chief Officer | Profile | |
| Amitai Gridish | Chief Ltd | Profile |
Other Information on Investing in Novolog Stock
Novolog Pharm financial ratios help investors to determine whether Novolog Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Novolog with respect to the benefits of owning Novolog Pharm security.